The Impact of Inherited Retinal Diseases in the United States of America (US) and Canada from a Cost-of-Illness Perspective
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To estimate the annual cost of inherited retinal diseases (IRDs) in the United States of America (US) and Canada from a societal perspective - including costs to the health system, individual and family productivity costs, lost wellbeing and other societal economic costs - by setting and payer. Findings will inform the need for policy action to mitigate the impact of IRDs. METHODS: The costs of IRDs were estimated using a cost-of-illness methodology, based on the prevalence of IRDs in each country. Intangible costs of reduced wellbeing were also estimated using disability-adjusted life years which were then converted to monetary values using the value of a statistical life. RESULTS: Using base prevalence rates, total costs attributable to IRDs in the US were estimated to range between US$13,414.0 and US$31,797.4 million in 2019, comprising both economic costs (between US$4,982 and US$11,753.9 million; 37% of total costs) and wellbeing costs (between US$8,431.7 and US$20,043.6 million; 63%). Total costs attributable to IRDs in Canada were estimated to range between CAN$1637.8 and CAN$6687.5 million in 2019, comprising both economic costs (between CAN$566.6 and CAN$2,305.7 million; 34%) and wellbeing costs (between CAN$1,071.4 and CAN$4,381.9 million; 66% of total costs). CONCLUSION: The impact of IRDs in the US and Canada is substantial when considering both economic costs and reduced wellbeing. The wellbeing costs due to IRDs in the US and Canada are considerable, accounting for over 60% of total costs. Vision loss from IRDs often manifests in childhood, meaning some people live with vision impairment and blindness for their whole lives. Further research into current and emerging cost-effective therapies and interventions is required given the substantial economic burden faced by those living with vision loss.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“other international studies suggested that 81% to 90% of the costs associated with IRDs are indirect and intangible [80–84].”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [81]
In the citing paper
“However, there is still a significant need for these products to reduce the high healthcare costs, economic burden, and costs to affected individuals and families and to improve patient well-being and quality of life.155”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [155]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
James, S. L., Abate, D., Abate, K. H., Abay, S. M., Abbafati, C., Abbasi, N., Abbastabar, H., Abd-Allah, F., Abdela, J., Abdelalim, A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32279-7 · Cited by 13,867
Vos, T., Abajobir, A. A., Abate, K. H., Abbafati, C., Abbas, K. M., Abd-Allah, F., Abdulkader, R. S., Abdulle, A. M., Abebo, T. A., Abera, S. F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32154-2 · Cited by 13,220
Petty, R. E., Southwood, T. R. E., Manners, P. J., Baum, J., Glass, D. N., Goldenberg, J., He, X.-H., Maldonado-Cocco, J. A., Orozco-Alcalá, J., Prieur, A., et al. (2004) · PubMed · Cited by 4,176
The Elasticity of Taxable Income with Respect to Marginal Tax Rates: A Critical Review
Saez, E., Slemrod, J., & Giertz, S. H. (2012) · Journal of Economic Literature · doi:10.1257/jel.50.1.3 · Cited by 1,299
A 2020 vision of patient-centered primary care
Davis, K., Schoenbaum, S. C., & Audet, A.-M. (2005) · Journal of General Internal Medicine · doi:10.1111/j.1525-1497.2005.0178.x · Cited by 683
Genes and mutations causing retinitis pigmentosa
Daiger, S. P., Sullivan, L. S., & Bowne, S. J. (2013) · Clinical Genetics · doi:10.1111/cge.12203 · Cited by 619
Centers for Medicare & Medicaid Services (CMS)
Services, U. S. C. F. M. M. (2013) · Cited by 318
Comparisons of Health Care Systems in the United States, Germany and Canada
Ridic, G., Gleason, S., & Ridic, O. (2012) · Materia Socio Medica · doi:10.5455/msm.2012.24.112-120 · Cited by 308
Zhang, X., Bullard, K. M., Cotch, M. F., Wilson, M. R., Rovner, B. W., McGwin, G., Owsley, C., Barker, L., Crews, J. E., & Saaddine, J. B. (2013) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2013.2597 · Cited by 293
Inherited Retinal Degenerations: Current Landscape and Knowledge Gaps
Duncan, J. L., Pierce, E. A., Laster, A. M., Daiger, S. P., Birch, D. G., Ash, J. D., Iannaccone, A., Flannery, J. G., Sahel, J. A., Zack, D. J., et al. (2018) · Translational Vision Science & Technology · doi:10.1167/tvst.7.4.6 · Cited by 257
Research works printed but not linked: 5
- Mayro, 2020, Eur J Ophthalmol, 1
- Fullerton, 2017, Natl Bureau Econ Res
- Baicker, 2011, Natl Bur Econ Res Bull Aging Health, 25, 39
- Canadian Arthritis Network. Canadian Arthritis Funding Landscape Review. Available from: https://www.arthrite.ca/AS/media/pdf/Researchers/Arthritis-Funding-Final-Final-Landscape-Review.pdf. Accessed March 10, 2021.
- Petty, 2004, J Rheumatol, 31, 390
Cited by
Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions
Drag, S., Dotiwala, F., & Upadhyay, A. K. (2023) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.64.7.39 · Cited by 145
Oxidative Stress: A Suitable Therapeutic Target for Optic Nerve Diseases?
Buonfiglio, F., Böhm, E. W., Pfeiffer, N., & Gericke, A. (2023) · Antioxidants · doi:10.3390/antiox12071465 · Cited by 78
Gene-Based Therapeutics for Inherited Retinal Diseases
Fenner, B. J., Tan, T., Barathi, V. A., Tun, S. B. B., Yeo, S. W., Tsai, A. S. H., Lee, S. Y., Cheung, C. M. G., Chan, C. M., Mehta, J. S., et al. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2021.794805 · Cited by 68
Stem cell therapy for inherited retinal diseases: a systematic review and meta-analysis
Chen, X., Xu, N., Li, J., Zhao, M., & Huang, L. (2023) · Stem Cell Research & Therapy · doi:10.1186/s13287-023-03526-x · Cited by 46
Gene Therapy for Inherited Retinal Diseases: From Laboratory Bench to Patient Bedside and Beyond
Brar, A. S., Parameswarappa, D. C., Takkar, B., Narayanan, R., Jalali, S., Mandal, S., Fujinami, K., & Padhy, S. K. (2023) · Ophthalmology and Therapy · doi:10.1007/s40123-023-00862-2 · Cited by 48
Chambers, C., Soo, G. L., Engel, A. L., Glass, I. A., Frassetto, A., Martini, P. G. V., & Cherry, T. J. (2024) · Translational Vision Science & Technology · doi:10.1167/tvst.13.7.7 · Cited by 38
Toward low-cost gene therapy: mRNA-based therapeutics for treatment of inherited retinal diseases
Antas, P., Carvalho, C., Cabral-Teixeira, J., de Lemos, L., & Seabra, M. C. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.11.009 · Cited by 36
Update on Clinical Trial Endpoints in Gene Therapy Trials for Inherited Retinal Diseases
Igoe, J., Lam, B. L., & Gregori, N. Z. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13185512 · Cited by 35
Cost-of-illness studies of inherited retinal diseases: a systematic review
Ng, Q. X., Ong, C., Yaow, C. Y. L., Chan, H. W., Thumboo, J., Wang, Y., & Koh, G. C. H. (2024) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-024-03099-9 · Cited by 27
“The need for lifelong monitoring and intervention further adds to the healthcare expenses [6, 7].”
BackgroundMethodInfluentialSchofield, D., Kraindler, J., Tan, O., Shrestha, R. N., West, S., Hart, N., Tan, L., Ma, A., Grigg, J. R., & Jamieson, R. V. (2023) · Medical Journal of Australia · doi:10.5694/mja2.51997 · Cited by 22
Impact of inherited retinal diseases on Canadian patients and families: a mixed-methods study
Kherani, I. Z., Andrews, C., Pereira, J. A., Moniz, L. S., & Qian, C. X. (2022) · Canadian Journal of Ophthalmology · doi:10.1016/j.jcjo.2022.06.021 · Cited by 18
Self-citationZebrafish models of inherited retinal dystrophies
Perkins, B. D. (2022) · Journal of Translational Genetics and Genomics · doi:10.20517/jtgg.2021.47 · Cited by 19
Chay, J., Tang, R. W. C., Tan, T.-E., Chan, C. M., Mathur, R., Lee, B. J. H., Chan, H. H., Sim, S. S. K. P., Farooqui, S., Teo, K. Y. C., et al. (2023) · Eye · doi:10.1038/s41433-023-02624-7 · Cited by 15
Watanabe, K., Aouadj, C., Hiratsuka, Y., Yamamoto, S., & Murakami, A. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02446-9 · Cited by 13
“…annual well-being costs (USA: 8432–20,044 million USD, Canada: 859–3514 million USD) of inherited retinal diseases than economic costs (USA: 4982–11,754 million USD, Canada: 455–1849 million USD); 1.247 Canadian dollars was converted to 1 USD to calculate the USD equivalent of each cost [36].”
InfluentialGarlasco, J., Nurchis, M. C., Bordino, V., Sapienza, M., Altamura, G., Damiani, G., & Gianino, M. M. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19084862 · Cited by 13
Kulbay, M., Tuli, N., Akdag, A., Ali, S. K., & Qian, C. X. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13144224 · Cited by 13
Cell-cell interaction in the pathogenesis of inherited retinal diseases
Du, X., Butler, A. G., & Chen, H. Y. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1332944 · Cited by 12
Paudel, N., Daly, A., Waters, F., & Stratieva, P. (2024) · Ophthalmic Research · doi:10.1159/000537818 · Cited by 11
Self-citationSocioeconomic burden of cystic fibrosis in Canada
Laflamme, O. D., Johnson, N., Steele, K., Chavez, L., Cheng, S. Y., Rabin, H. R., Cheema, Z. M., Mamic, E., Gomez, L. C., Leong, J., et al. (2024) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2024-002309 · Cited by 10
Calzetti, G., Schwarzwälder, K., Ottonelli, G., Kamińska, K., Strauss, R. W., Baere, E. D., Leroy, B. P., Audo, I. S., Zeitz, C., Cursiefen, C., et al. (2024) · Ophthalmic Research · doi:10.1159/000540607 · Cited by 10
The State of Patient-Reported Outcome Measures for Pediatric Patients with Inherited Retinal Disease
Selvan, K., Abalem, M. F., Lacy, G. D., Vincent, A., & Héon, E. (2022) · Ophthalmology and Therapy · doi:10.1007/s40123-022-00514-x · Cited by 10
Thirunavukarasu, A. J., Raji, S., & Cehajic‐Kapetanovic, J. (2025) · Gene Therapy · doi:10.1038/s41434-025-00552-7 · Cited by 10
Thompson, D. A., Jayasundera, T., Alekseev, O., Ali, R. R., Amato, A., Arshavsky, V. Y., Audo, I. S., Auricchio, A., Bainbridge, J. W., Banin, E., et al. (2025) · Translational Vision Science & Technology · doi:10.1167/tvst.14.8.37 · Cited by 8
Rationale and protocol paper for the Asia Pacific Network for inherited eye diseases
Wong, W., Tham, Y. C., Simunovic, M. P., Chen, F. K., Luu, C. D., Chen, H., Jin, Z., Shen, R., Li, S., Sui, R., et al. (2024) · Asia-Pacific Journal of Ophthalmology · doi:10.1016/j.apjo.2023.100030 · Cited by 8
Current approaches for Usher syndrome disease models and developing therapies
Leith, F. K., Lye, J., Delaney, D. S., McLenachan, S., Chen, F. K., Atlas, M. D., & Wong, E. Y. M. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1547523 · Cited by 8
Therapies for Inherited Retinal Dystrophies: What is Enough?
Leroy, B. P., Daly, A., Héon, E., Sahel, J., & Dollfus, H. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104095 · Cited by 7
Self-citationOh, R., Woo, S. J., & Joo, K. (2023) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-023-06309-5 · Cited by 6
Bušányová, B., Vajter, M., Kelifová, S., Lišková, P., Miková, H., Breciková, K., Zigmond, J., Rogalewicz, V., Tichopád, A., Višňanský, M., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e32296 · Cited by 6
The Landscape of Genomic Services for Inherited Retinal Degenerations (IRDs) Across Europe
Paudel, N., Daly, A., Moran, E. M., & Stratieva, P. (2024) · Clinical ophthalmology · doi:10.2147/opth.s465930 · Cited by 6
Self-citationHitch, J., Denee, T. R., Brassel, S., Lee, J., Michaelides, M., Petersen, J. S., Alulis, S., & Steuten, L. (2024) · Value in Health · doi:10.1016/j.jval.2024.08.009 · Cited by 6
“Blindness” is not a contraindication for voretigene neparvovec-rzyl treatment: a review of 9 cases
Parameswarappa, D. C., Stephenson, K. A. J., Seamone, M. E., Qian, C. X., Muni, R. H., Kertes, P. J., Vincent, A., & Héon, E. (2025) · Canadian Journal of Ophthalmology · doi:10.1016/j.jcjo.2024.12.013 · Cited by 6
CRB1 -Associated Retinal Dystrophy Patients Have Expanded Lewis Glycoantigen-Positive T Cells
Moekotte, L., Kuiper, J. J. W., Hiddingh, S., Nguyen, X., Boon, C. J. F., van den Born, L. I., de Boer, J. H., & van Genderen, M. M. (2023) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.64.13.6 · Cited by 6
Gocuk, S. A., Edwards, T. L., Jolly, J. K., & Ayton, L. N. (2023) · Clinical Genetics · doi:10.1111/cge.14442 · Cited by 5
The socioeconomic epidemiology of inherited retinal diseases in Portugal
Marta, A. A., Marques, J. P., Santos, C., Coutinho-Santos, L., Vaz-Pereira, S., Costa, J. F., Arede, P., Félix, R., Geada, S., Gouveia, N. M. S., et al. (2024) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-024-03161-6 · Cited by 5
Yin, G. S., Shao, Z., Faghfoury, H., & Ballios, B. G. (2024) · Ophthalmology Retina · doi:10.1016/j.oret.2024.08.007 · Cited by 5
Artificial intelligence applications in inherited retinal dystrophies
Király, P., & Fischer, M. D. (2025) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-025-06956-w · Cited by 4
Inherited retinal degenerations: clinical phenotypes and emerging therapies
Uyhazi, K. E., O'Neil, E. C., Alemán, T. S., & Cideciyan, A. V. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00766-x · Cited by 4
Inherited retinal disease in global Indigenous populations: A scoping review
Crutchfield, E. C. T., Vincent, A. L., Anjou, M. D., Taylor, H. R., Tatipata, S., Tsosie, K. S., Carvalho, L. S., Ayton, L. N., & Britten‐Jones, A. C. (2025) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2025.06.005 · Cited by 4
Diagnostic Challenges in ABCA4-Associated Retinal Degeneration: One Gene, Many Phenotypes
Tan, T., Tang, R. W. C., Chan, C. M., Mathur, R. S., & Fenner, B. J. (2023) · Diagnostics · doi:10.3390/diagnostics13233530 · Cited by 6
Moussallem, L., Lombardi, L., McGuinness, M. B., Kolic, M., Baglin, E. K., Jin, R., Habili, N., Kvansakul, J. G. S., Titchener, S. A., Abbott, C. J., et al. (2025) · Journal of Neural Engineering · doi:10.1088/1741-2552/adc83a · Cited by 3
Ribeiro, P. V. Z., Mitre, L. P., Gauza, M. D. M., Furukawa, P. H., Ferraz, V. E. D. F., & Gomy, I. (2025) · Ophthalmic Genetics · doi:10.1080/13816810.2025.2521647 · Cited by 2
Pechhacker, M. K. G., Molnar, A. E. C., Pacheco, N. P., Thonberg, H., Quérat, L., Birkeldh, U., Nordgren, A., & Lindstrand, A. (2023) · Ophthalmic Genetics · doi:10.1080/13816810.2023.2215332 · Cited by 2
Inherited retinal dystrophies and orphan designations in the European Union
Moseley, J., Leest, T., Larsson, K., Magrelli, A., & Stoyanova-Beninska, V. V. (2024) · European Journal of Ophthalmology · doi:10.1177/11206721241236214 · Cited by 2
Leber hereditary optic neuropathy in Slovenia: quality of life and costs from patient perspective
Hawlina, M., Kovač, L., Breciková, K., Zigmond, J., Rogalewicz, V., Tichopád, A., Višňanský, M., & Šarkanová, I. (2024) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-024-03329-0 · Cited by 2
Herce-Hagiwara, B., McKenna, A., Makam, A. N., Richardson, M., Lee, W., Phillips, M., Rind, D. M., & Agboola, F. O. (2025) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2025.31.8.835 · Cited by 2
Marta, A. A., Miranda, V., Lume, M., Parreira, R., Soares, C. A., Menéres, M. J., Lemos, C., & Beirão, J. M. (2023) · Ophthalmology Science · doi:10.1016/j.xops.2023.100443 · Cited by 2
Paudel, N., & Daly, A. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1481670 · Cited by 1
Self-citationPharmakotherapie von ABCA4-assoziierten Netzhautdystrophien
Gerhardt, M. J., Štingl, K., & Reith, M. (2025) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/a-2533-1009 · Cited by 1
Demas, N., Estrada, C., Morales, P., Jacobs, M., Kitchens, J. W., Pearson, P. A., & Maldonado, R. S. (2025) · BMC Medical Genomics · doi:10.1186/s12920-025-02186-5 · Cited by 1
Net present value cost analysis for treating retinitis pigmentosa
Hellems, S. S., Puri, S., Yip, S., Fehr, J., & Milentijevic, D. (2025) · Journal of Medical Economics · doi:10.1080/13696998.2025.2559533 · Cited by 1
Patient-Reported Social Impact of Molecularly Confirmed Macular Dystrophies and Cone–Rod Dystrophies
Zehe-Lindau, N., Lindau, B., Stöhr, H., Weber, B. H. F., Spital, G., & Kellner, U. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14227928 · Cited by 1
AlEissa, M. M., Abedalthagafi, M., & Edward, D. (2026) · Frontiers in Ophthalmology · doi:10.3389/fopht.2025.1660483 · Cited by 1
Gene therapy outcomes in young patients with RPE65-retinal degeneration
STEPHENSON, K., Alsalamah, A. K., Tumber, A. K., Mercer, G., Ballios, B. G., Muni, R. H., Tavares, E. S., Kertes, P. J., Vincent, A., & Héon, E. (2026) · Canadian Journal of Ophthalmology · doi:10.1016/j.jcjo.2026.01.016 · Cited by 1
Modalities of vision restoration in optic neuropathies and retinal disease
Rubin, B. R., Lavinsky, F., Cain, R., Kuriyan, A. E., Wollstein, G., Zambrano, R., & Schuman, J. S. (2026) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2026.101474 · Cited by 1
Disparities in Inherited Retinal Degenerations
Chorfi, S., Place, E., & Huckfeldt, R. M. (2022) · Seminars in Ophthalmology · doi:10.1080/08820538.2022.2152715 · Cited by 2
Willmington, C., Kirby, A., & Murphy, A. (2025) · Health Economics Review · doi:10.1186/s13561-025-00707-7
Cone Dysfunction Syndromes, Cone Dystrophies, and Cone-Rod Degenerations
Hull, S., & Traboulsi, E. I. (2025) · Oxford University Press eBooks · doi:10.1093/med/9780197659403.003.0032
Felfeli, T., Fang, H., Gauthier‐Loiselle, M., Jiang, F., & Mandelcorn, E. D. (2025) · Canadian Journal of Ophthalmology · doi:10.1016/j.jcjo.2025.11.002
MODELING NATURAL HISTORY AND COST-EFFECTIVENESS OF GENE-AGNOSTIC TREATMENT IN RETINITIS PIGMENTOSA
Sullivan, P. W., Wertheimer, A. I., Grover, S., & Jayasundera, K. T. (2025) · Retina · doi:10.1097/iae.0000000000004735
Additional file 1 of Cost-of-illness studies of inherited retinal diseases: a systematic review
Ng, Q. X., Ong, C., Yaow, C. Y. L., Chan, H. W., Thumboo, J., Wang, Y., & Koh, G. C. H. (2024) · Figshare · doi:10.6084/m9.figshare.26687112
Shrewsbury, A. M. (2023) · eScholarship (California Digital Library)
Terapias Genéticas para Distrofias Maculares: Estratégias atuais e perspetivas futuras
Bastos, T. A. C. P. (2025) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Selvan, K. (2023) · TSpace (University of Toronto)
Wang, B., Ganzen, L. C., Coskun, E., James, R., Kha, T., Zhu, X., New, J. A., Tsujikawa, M., & Leung, Y. F. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.18.719270
Assessment of the Lifetime Costs of Severe Visual Impairment Due to Retinitis Pigmentosa
Milentijevic, D., Ferro, C., Rosenblum, S., & Dieguez, G. (2026) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s571305
SCHOFIELD, D. J., Kraindler, J., Shrestha, R. N., Tan, O., West, S., Hart, N., Wall, L., Tan, L., Hewett, D., Villaret, L., et al. (2026) · Eye · doi:10.1038/s41433-026-04532-y
Downregulating Nrl Expression and Rod Photoreceptor Protection
Li, Y., Jiao, S., Tao, W., & Wen, R. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27114683
Gene therapy development for retinal diseases
Reichel, F. F., Bellingrath, J.-S., Király, P., & FISCHER, M. D. (2026) · Handbook of clinical neurology · doi:10.1016/b978-0-443-22212-2.00016-1
Global disparities in inherited retinal disease: A scoping review
Yu, J. H., Adams, A. R., See, W. Y. N., & Ahmed, I. (2026) · AJO International · doi:10.1016/j.ajoint.2026.100299
A national cross-sectional study of patients with inherited retinal disease in China
Zhang, Y., Chen, M., Duan, Z., Yang, P., Xie, L., & Zhisheng, Y. (2026) · Scientific Reports · doi:10.1038/s41598-026-70895-7
Metadata
- Authors
- Gong, J., Cheung, S., Fasso-Opie, A., Galvin, O., Moniz, L. S., Earle, D., Durham, T., Menzo, J., Li, N., Duffy, S., Dolgin, J., Shearman, M. S., Fiorani, C., Banhazi, J., & Daly, A.
- Affiliations
- Foundation Fighting Blindness (US)
- Applied Genetic Technologies (United States) (US)
- Novartis (Switzerland) (CH)
- Corresponding author
- Daly, Avril
- Venue
- Clinical Ophthalmology
- Publisher
- Informa UK Limited
- Published
- 2021-07
- Volume
- Volume 15
- Pages
- 2855-2866
- ISSN
- 1177-5467 (ISSN-L)
- 1177-5483
- PMC
- PMC8257071
- OpenAlex
- W3175694094
- Cited by
- 64
- References
- 19
- Citations by year
- 2026: 9 · 2025: 18 · 2024: 17 · 2023: 14 · 2022: 6
- FWCI
- 7.06
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Clinical ophthalmology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- inherited retinal disease, economic burden, disability-adjusted life years, value of a statistical life, vision loss, productivity costs, health system costs, blindness, prevalence, United States, Canada
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

